(R)-2-(5-氰基-6-氟-8-甲基-1-丙基-1,3,4,9-四氢吡喃o[3,4-b]吲哚-1-基)乙酸 | 627871-22-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: (R)-2-(5-氰基-6-氟-8-甲基-1-丙基-1,3,4,9-四氢吡喃o[3,4-b]吲哚-1-基)乙酸
• 英文名称: [(1R)-5-cyano-6-fluoro-8-methyl-1-propyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl]acetic acid
• 英文别名: [(R)-5-cyano-6-fluoro-8-methyl-1-propyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl]acetic acid；(R)-5-cyano-6-fluoro-8-methyl-1-propyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid；(R)-2-(5-Cyano-6-fluoro-8-methyl-1-propyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl)acetic acid；2-[(1R)-5-cyano-6-fluoro-8-methyl-1-propyl-4,9-dihydro-3H-pyrano[3,4-b]indol-1-yl]acetic acid
• CAS: 627871-22-1
• 化学式: C₁₈H₁₉FN₂O₃
• 分子量: 330.359
• InChiKey: BLMMDSMMSYATKY-GOSISDBHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  86.1
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 海关编码：
  2934999090

反应信息

• 作为产物：
  描述：

  5-cyano-6-fluoro-8-methyl-1-propyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid ethyl ester 在 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 (R)-2-(5-氰基-6-氟-8-甲基-1-丙基-1,3,4,9-四氢吡喃o[3,4-b]吲哚-1-基)乙酸
  参考文献：
  名称：

  Discovery of Pyrano[3,4-b]indoles as Potent and Selective HCV NS5B Polymerase Inhibitors

  摘要：

  A novel series of HCV NS5B RNA-dependent RNA polymerase inhibitors containing a pyrano-[3,4-b]indole scaffold is described leading to the discovery of compound 16, a highly potent and selective inhibitor that is active in the replicon system.

  DOI：

  10.1021/jm0401255

文献信息

• [EN] METHOD FOR THE USE OF PYRANOINDOLE DERIVATIVES TO TREAT INFECTION WITH HEPATITIS C VIRUS<br/>[FR] METHODE D'UTILISATION DE DERIVES DU PYRANOINDOLE POUR TRAITER UNE INFECTION PAR LE VIRUS DE L'HEPATITE C
  申请人：WYETH CORP

  公开号：WO2003099275A1

  公开（公告）日：2003-12-04

  The invention is directed to methods of treating, preventing, or inhibiting a Hepatitis C viral infection in a mammal comprising containing the mammal with an effective amount of a compound of the formula: Wherein substitutions at R1, R2, R3-R12, and Y are set forth in the specification.

  这项发明涉及治疗、预防或抑制哺乳动物体内丙型肝炎病毒感染的方法，包括使用有效量的符合以下结构式的化合物来处理哺乳动物：其中R1、R2、R3-R12和Y的取代基在说明书中列出。
• [EN] R-ENANTIOMERS OF PYRANOINDOLE DERIVATIVES AGAINST HEPATITIS C<br/>[FR] ENANTIOMERES R DE DERIVES DE PYRANO-INDOLE DIRIGES CONTRE L'HEPATITE C
  申请人：WYETH CORP

  公开号：WO2003099824A1

  公开（公告）日：2003-12-04

  The invention is directed to a compound and a pharmaceutical composition of the formula: Wherein substitutions at R1, R2, R3 - R12, and Y are set forth in the specification.

  该发明涉及一种化合物和一种药物组合物，其化学式为：其中R1、R2、R3 - R12和Y的取代基在说明书中给出。
• Method for the use of pyranoindole derivatives to treat infection with Hepatitis C virus
  申请人：Wyeth

  公开号：US20040082643A1

  公开（公告）日：2004-04-29

  The invention is directed to methods of treating, preventing, or inhibiting a Hepatitis C viral infection in a mammal comprising contacting the mammal with an effective amount of a compound of the formula: 1 Wherein substitutions at R 1 , R 2 , R 3 -R 12 , and Y are set forth in the specification.

  本发明涉及一种用于治疗、预防或抑制哺乳动物体内丙型肝炎病毒感染的方法，包括将哺乳动物与公式1中的化合物的有效量接触。其中，R1、R2、R3-R12和Y的取代基在规范中说明。
• R-enantiomers of pyranoindole derivatives and the use thereof for the treatment of hepatitis C virus infection or disease
  申请人：Wyeth

  公开号：US20040029947A1

  公开（公告）日：2004-02-12

  The invention is directed to a compound and a pharmaceutical composition of the formula: 1 Wherein substitutions at R 1 , R 2 , R 3 -R 12 , and Y are set forth in the specification.

  该发明涉及一种化合物和药物组合物，其化学式为：1，其中R1、R2、R3-R12和Y的取代基在说明书中给出。
• Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
  申请人：Oka Takahiro

  公开号：US20070049593A1

  公开（公告）日：2007-03-01

  The present invention relates to a tetracyclic fused heterocyclic compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable a salt thereof, and a hepatitis C virus (HCV) polymerase inhibitor and a therapeutic agent for hepatitis C containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

  本发明涉及一种四环融合杂环化合物，其化学式为[I]，其中每个符号的定义如规范中所述，或其药学上可接受的盐，以及一种丙型肝炎病毒（HCV）聚合酶抑制剂和治疗丙型肝炎的药物，本发明的化合物表现出基于HCV聚合酶抑制活性的抗HCV活性，因此可用作预防或治疗丙型肝炎的药物。